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Abstract: Molecular-dynamics simulations with metadynamics 
enhanced sampling reveal three distinct binding sites for arginine 
vasopressin (AVP) within its V2-receptor (V2R). Two of these, the 
vestibule and intermediate sites, block (antagonize) the receptor and 
the third is the orthosteric activation (agonist) site. The contacts found 
for the orthosteric site satisfy all the requirements deduced from 
mutagenesis experiments. Metadynamics simulations for V2R and its 
V1aR-analog give an excellent correlation with experimental binding 
free energies by assuming that the most stable binding site in the 
simulations corresponds to the experimental binding free energy in 
each case. The resulting three-site mechanism separates agonists 
from antagonists and explains subtype selectivity. 
G-protein coupled receptors (GPCRs) represent one of nature’s 
most successful designs. They not only control many biological 
processes but are also remarkably versatile. One receptor can 
exert control mechanisms via one or more G-proteins and/or the 
arrestin pathway. These pathways involve intracellular binding 
partners that have been shown[1] to affect ligand binding in accord 
with the ternary-complex model.[2] GPCR ligands are also diverse 
in function; they may be agonists, antagonists, inverse or partial 
agonists and act differently on the alternative pathways (biased 
agonists). They account for approximately 40% of all marketed 
drugs.[3] Much remains unknown about the mechanisms for these 
diverse functions. Even though high-resolution crystal structures 
have contributed substantially to clarifying the structure and 
function of GPCRs, they capture only static snapshots that occur 
within very complex molecular mechanisms. Molecular-dynamics 
(MD) simulations represent one of the few possibilities to extend 
the information provided by crystallographic structures to reveal 
the atomistic details of GPCR-activation.[4] 
The vasopressin receptors are GPCR drug targets, in particular 
for antidiuresis and vasopression.[5] Their natural ligand in 
mammals is arginine vasopressin (AVP, Cys-Tyr-Phe-Gln-Asn-
Cys-Pro-Arg-Gly-NH2). AVP is closely related to the non-
mammalian lysine-vasopressin, oxytocin and urotensin, which all 
exhibit six-residue rings closed by a disulfide bond. The ring can 
exhibit different conformations, both in different crystal 
structures[6] and solution.[7]  
Three different AVP-receptor-subtypes are known: V1aR, V1bR 
and V2.[8] V2R is localized in the renal collecting duct[9] and 
associated with nephrogenic diabetes insipidus (NDI).[10] Only two 
non-peptide ligands for this target, the V2R/V1aR-antagonist 
conivaptan 1 and the V2R-antagonist tolvaptan 2 (Scheme 1) 
have received FDA approval, although the selective V2R-agonist 
peptide desmopressin remains the drug of choice for NDI. [11]  
No crystal structures are available for the vasopressin-receptors 
but abundant mutagenesis data exist.[8a] The N-terminus and first 
extracellular loop (ECL1) of V1aR are essential for ligand binding. 
The hydrophilic residues Gln1082.61, Lys1283.29, Gln1313.32 and 
Gln1854.60 in V1aR contribute to both AVP binding and its ability to 
activate vasopressin receptors.[12] No binding pose that satisfies 
all these contacts has been proposed for AVP in its receptors. 
Scheme 1. Conivaptan 1, Tolvaptan 2, Lixivaptan 3, Satavaptan 
4 and MCF18, 5. 
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We now report a computational study of the AVP/V2R system. It 
not only reveals a binding pose compatible with all the V1aR 
mutation data and a quantitative model for ligand binding in V1aR 
and V2R but also proposes a new mechanism for the modes of 
action of different ligand types. 
A homology model (see the Supporting Materials, SM) was 
refined using a 1 s MD-simulation, above all to equilibrate the 
loops and the modeled N-terminus. This subdomain folded to form 
hydrogen bonds with the receptor surface and remained stable for 
the last 900 ns of the simulation. Although we cannot be sure, the 
simulation suggests that the receptor has reached a stable 
conformation. The N-terminal insertion quickly adopted a 
conformation resembling those of the neurotensin 1 and μ-opioid 
receptors,[1c,13] (see Fig. S1 of the SM). Otherwise, the simulation 
changed little from the homology model.  
Two 6.5 s MD-simulations in which two AVP molecules were 
initially placed in the extracellular solvent above the receptor 
surface were performed. One resulted in an AVP molecule 
docking into a vestibule complex that remains stable for the final 
six s of the simulation (Fig. 1). These simulations indicate an 
energy barrier between the vestibule complex and deeper binding 
pockets. This barrier was first reported by Dror et al. using 
unbiased MD simulations on the β2-adrenergic receptor[14] and 
extended to the muscarinic M2 and M3 receptors using both 
unbiased[15] and accelerated MD (enhanced sampling).[16] The 
ligand paused in a vestibule position (between ECL2 and ECL3) 
before moving into multiple deeper binding sites, including 
intermediate and orthosteric sites.[14,17] However, the magnitude 
of the barriers between the sites and their relative free-energy 
differences were not quantified. Vestibule complexes have been 
found, for instance, for the muscarinic M2[18] and M3[15] receptors 
and the extracellular loops are known to play important roles in 
the biology of GPCRs.[19] As these simulations suggested the 
existence of at least two binding sites (vestibule and orthosteric), 
we investigated the binding path using metadynamics simulations.  
Adaptive biasing force simulations[20] provided an initial guess for 
possible binding pathways for metadynamics simulations on the 
binary AVP-V2R complex (see the SM and Fig. S2 for details). We 
used a combination of funnel metadynamics[21] in its well-
tempered variant[22] and a path collective variable (PCV),[23] a 
combination that has proven to be very effective for investigating 
protein-ligand interactions.[20,24] Three walkers were placed along 
the path using the multiple walker technique.[25] Fig. 2 shows a 
projection of the free-energy landscape onto the path variables 
and the main minima and barriers involved in binding. The 
simulation converged after more than 3.9 μs to reveal three 
energy minima (see Fig. S3) that correspond to:  
1. The vestibule complex (binding free energy, calculated GB = 
11.6 kcal mol-1),  
2. An intermediate binding site (calculated GB = -10.3 kcal mol1) 
separated by a low barrier from the vestibule binding site and a 
higher one (calculated barrier 15 kcal mol1) from the orthosteric 
site, and  
3. An orthosteric-binding site that satisfies all interactions required 
by the mutagenesis studies for AVP to interact and activate the 
vasopressin receptors. This site is the most stable of the three 
with a calculated GB of 12.6 kcal mol-1 (experimental Ki=0.78 
nM = 12.9 kcal mol-1). Figure S3 of the SM shows the contacts 
between ligand and receptor found for these three complexes.  
Fig. 1. A representative average structure of the stable AVP-V2R extracellular vestibule complex obtained from the unbiased 6.5 μs 
MD simulation. 
The calculated GB is most negative for the orthosteric site and 
agrees very well with experiment. However, both the vestibule 
and intermediate sites correspond to metastable minima in the 
free energy landscape and might be druggable. The large barrier 
between the intermediate and orthosteric sites (the “activation 
barrier”) strongly suggests a cooperative mechanism between the 
G-protein (or -arrestin) and a ligand for receptor activation. We 
hypothesize that ligand binding in the intermediate site of the 
receptor in the absence of an intracellular protein binding partner 
cannot lead to activation because the intermediate site blocks the 
orthosteric one, which is known[2] to lead to activation (black 
profile in Fig. 2B). Furthermore, a plausible cooperative activation 
mechanism is that the activation barrier is lower in the ternary 
complex than in the binary one, so that the orthosteric site can be 
populated in the presence of the G-protein and receptor activation 
can occur. This hypothetical barrier lowering (blue profile in Fig. 
2B) results from the extra stabilization of the ligand binding to the 
orthosteric site, as proposed by the ternary complex model.[1,20] In 
the ternary complex model, the ligand and the G-protein 
cooperate to reinforce binding to the orthosteric site. This 
stabilization should also result in a lowering of the activation 
barrier, as indicated in Figure 2B. 
In order to test this interpretation, we simulated four non-peptide 
ligands to investigate the subtype and functional selectivity toward 
V1aR and V2R. The V2R structure after 7.5 μs MD simulation was 
used as a template to construct a model for V1aR, which was then 
refined by 0.5 s of MD simulation. The ligands were a non-
selective V2/V1a antagonist 1,[26] a selective V2 antagonist 3,[27] a 
functionally selective V2 modulator (Gs antagonist/arrestin partial 
agonist) 4[28] and a functionally selective V2 modulator (Gs agonist) 
5.[29] The experimental free binding energies were derived from 
the corresponding binding constants, which are shown in Table 1.  
The free-energy profiles obtained from metadynamics simulations 
(Fig. 3) all indicate that V2R always favors the vestibule, and V1aR 
the intermediate site. Note that the three-site model leads to the 
unusual prediction that competitive antagonists need not bind to 
the same site as the agonists that they displace. This is because 
ligands in both the vestibule and the intermediate sites block 
access to the orthosteric site so that, once it has left the receptor, 
an agonist can no longer bind in the presence of an antagonist in 
one of the non-activating sites. It is known[30] that the important 
residues for non-peptide antagonist binding to V1aR are different 
to those involved in agonist binding.[31] 
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Figure 2. A) The free energy hypersurface obtained from the metadynamics simulation using the path PCV as a function of the 
progression on the path s(R) (a dimensionless number representing the relative position on the path) and the distance from the 
path s(Z) in nm (see the SM for more information). B) A schematic diagram of the energy levels found for AVP bound to V2R. The 
dotted arrows give energy differences (binding free en rgies or free energies of activ tion) in kcal mol-1. The blue arrows and 
energy levels show the hypothetical effect of binding a G-protein or -arrestin. The experimental binding free energy is shown in 
parentheses. 
Hypothetical effect of G-protein binding 
Table 1. Binding affinities (Ki in nM) of the non-peptide ligands used in this study, the experimental free energy of binding, ΔGB is 
calculated using ∆GB=RT ln(Ki) (T = 298K) and the calculated one is taken from the depths of the corresponding minima in the 
metadynamics profiles shown in Figure 3 (both in kcal mol-1). The assignments of the binding sites refer to the simulations and 
errors to the funnel sampling next to the global minima according to the scheme reported by Saladino et al. [32] The underlined 
simulation data are used in the correlation shown in Figure 4. 
Ligand Effect 
V1aR  V2R 
Site Experiment Simulation  Site Experiment Simulation 
   Ki GB GB   Ki GB GB 
Conivaptan, 1[26] Non-selective antagonist Intermediate 0.43 -13.0 -11.5  0.9  Vestibule 0.36 -12.9 -11.4  0.5 
Lixivaptan, 3[27] Selective V2-antagonist Intermediate 44 -10.1 -9.5  1.7  Vestibule 2.3 -11.9 -10.7  0.2 
Satavaptan, 4[28] Selective V2-biased 
selective G-antagonist 
and partial arrestin 
agonist 
Orthosteric 460 -8.7 -9.1  1.1  Vestibule 
0.54 -12.7 
-11.0  0.7 
Intermediate -8.0  1.1  
MCF18, 5[29] V2-Selective GS agonist Intermediate 106 -9.6 -9.1  1.2  Orthosteric 
20 -10.5 
-10.1  2.3 
 Vestibule -10.6  2.3 
 
 
Is the three-site model compatible with the known facts? Fig. 4 
shows a correlation of the experimental binding free energies 
against those found for the most stable binding site in Figures 3A-
D (the calculated GB). This correlation is good (R2 = 0.93), even 
though it involves three different types of binding site. This 
agreement can be seen to support the three-site model. The 
simplest hypothesis is that any ligand that binds most strongly to 
the orthosteric binding site will be an agonist. Partial agonists 
most likely bind in equilibrium between the orthosteric and either 
the intermediate or vestibule sites. Antagonists may bind to either 
the vestibule or intermediate site (or both). The observed behavior 
of ligands 1, 3 and 4 is consistent with this picture. MCF18, 5, 
gives the least clear picture. It activates less strongly than AVP 
but binds only weakly, so that its experimental classification is 
ambiguous.  
The simulations have provided a wealth of information and a new 
hypothesis that explains many features of the complex interplay 
between GPCRs, their ligands and their intracellular binding 
partners. Previous free-energy perturbation simulations have 
been used successfully to predict relative binding-free-energy 
differences (ΔΔG) between GPCR-ligands.[33] However, as far as 
we are aware, the current simulations are unique because they 
provide absolute binding energies with unprecedented accuracy, 
classify unknown ligands as agonists, antagonists or partial 
agonists and reveal unsuspected sources of subtype-specificity 
such as, for instance, the fact that antagonists bind to a different 
site (vestibule) in V2R than in V1aR (intermediate). It now remains 
to test this hypothesis for other GPCRs and to demonstrate that 
simulations can reproduce the effect of the intracellular binding 
partner on ligand binding and vice versa. Above all, however, this 
work has demonstrated the power of modern hard- and software 
combinations in GPCR research.  
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Figure 3. Free-energy profiles from the metadynamics simulations of A) Conivaptan 1, B) Lixivaptan 3, C) Satavaptan 4 
and D) MCF18 5. The approximate value-ranges for the path coordinate for the three sites are: orthosteric 0.5-0.7 nm, 
intermediate 0.7-1.0 nm and vestibule 1.4-1.6 nm. However, the reaction coordinate does not distinguish well between 
orthosteric and intermediate around 0.7 nm, so that visual inspection and contacts to the receptor were also used to 
assign the sites (See Fig. S4). The simulation binding energies listed in Table 1 refer to the depths of the corresponding 
minima in these curves. The free energy scale is relative to the separated ligand and receptor. 
Figure 4. Correlation of the calculated and experimental free 
binding energies for four V1aR and V2R ligands (data from 
Table 1 and binding-site assignments from Fig. 3). The two 
open circles indicate less stable alternative binding sites for 
Satavaptan and MCF18 that are not included in the correlation. 
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